{"disease":{"id":"advanced-inoperable-non-small-cell-lung-cancer","name":"advanced inoperable non small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01802632","title":"AZD9291 First Time In Patients Ascending Dose Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":603,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02157883","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02163733","title":"Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}